stoxline Quote Chart Rank Option Currency Glossary
  
Entera Bio Ltd. (ENTX)
0.66  -0.005 (-0.79%)    12-07 15:50
Open: 0.675
High: 0.7
Volume: 10,750
  
Pre. Close: 0.66525
Low: 0.6421
Market Cap: 19(M)
Technical analysis
2023-12-07 4:20:22 PM
Short term     
Mid term     
Targets 6-month :  0.8 1-year :  0.88
Resists First :  0.69 Second :  0.75
Pivot price 0.7
Supports First :  0.57 Second :  0.48
MAs MA(5) :  0.67 MA(20) :  0.7
MA(100) :  0.7 MA(250) :  0.81
MACD MACD :  -0.1 Signal :  0
%K %D K(14,3) :  44.8 D(3) :  50.6
RSI RSI(14): 45.4
52-week High :  1.48 Low :  0.51
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ENTX ] has closed above bottom band by 8.2%. Bollinger Bands are 21% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.7 - 0.71 0.71 - 0.71
Low: 0.63 - 0.64 0.64 - 0.64
Close: 0.65 - 0.66 0.66 - 0.67
Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Headline News

Tue, 14 Nov 2023
Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral ... - Yahoo Finance

Thu, 09 Nov 2023
Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has ... - Yahoo Finance

Tue, 12 Sep 2023
Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and ... - Yahoo Finance

Wed, 07 Jun 2023
Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors - GlobeNewswire

Wed, 31 May 2023
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn Rate - Simply Wall St

Fri, 31 Mar 2023
Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Outperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Outperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Neutral
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 29 (M)
Held by Insiders 1.958e+007 (%)
Held by Institutions 23 (%)
Shares Short 50 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS -1.039e+007
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin -74 %
Return on Assets (ttm) 664.2 %
Return on Equity (ttm) -54.3 %
Qtrly Rev. Growth 14000 %
Gross Profit (p.s.) 0
Sales Per Share -51.96
EBITDA (p.s.) 17741.9
Qtrly Earnings Growth -0.4 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow -7 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.02
Price to Cash Flow 5.58
Stock Dividends
Dividend 0
Forward Dividend 70460
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android